Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment

Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Nano letters Ročník 23; číslo 2; s. 476 - 490
Hlavní autori: Jung, Mungyo, Kim, Hyeongseop, Hwang, Jung Won, Choi, Yejoo, Kang, Mikyung, Kim, Cheesue, Hong, Jihye, Lee, Na Kyung, Moon, Sangjun, Chang, Jong Wook, Choi, Suk-joo, Oh, Soo-young, Jang, Hyemin, Na, Duk L., Kim, Byung-Soo
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States American Chemical Society 25.01.2023
Predmet:
Aged
Alzheimer Disease - metabolism
Alzheimer Disease - therapy
Animals
Cell Differentiation
Humans
Magnetic Iron Oxide Nanoparticles
Mesenchymal Stem Cells
Mice
Neurodegenerative Diseases
Wharton Jelly
magnetic guidance
Alzheimer’s disease
iron oxide nanoparticles
Mesenchymal stem cells
ISSN:1530-6984, 1530-6992, 1530-6992
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Wharton’s jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebro­ventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Wharton’s jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1530-6984
1530-6992
1530-6992
DOI:10.1021/acs.nanolett.2c03682